Sacituzumab Govitecan

Last Updated: 04/28/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 667 publications

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

PMDA regulatory update on approval and revision of the precautions for use of anticancer drugs in Japan; trastuzumab deruxtecan for solid tumors, talazoparib for prostate cancer, sacituzumab govitecan for breast cancer, darolutamide for salivary gland cancer, risovalisib for ovarian cancer, and mosunetuzumab plus polatuzumab vedotin for lymphoma.

Journal: International journal of clinical oncology

Published: April 09, 2026

The Importance of 5-hmC Expression Loss in Diagnosis of Mesothelioma and the Relationship Between TROP2 Expression and Histomorphological Parameters in Mesotheliomas.

The Importance of 5-hmC Expression Loss in Diagnosis of Mesothelioma and the Relationship Between TROP2 Expression and Histomorphological Parameters in Mesotheliomas.

Journal: International journal of surgical pathology

Published: April 06, 2026

Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer. Reply.

Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer. Reply.

Journal: The New England journal of medicine

Published: March 26, 2026

Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer.

Sacituzumab Govitecan in Advanced Triple-Negative Breast Cancer.

Journal: The New England journal of medicine

Published: March 26, 2026

TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer.

TROP2/claudin program mediates immune exclusion to impede checkpoint blockade in breast cancer.

Journal: Journal for immunotherapy of cancer

Published: March 25, 2026

Expert consensus on the clinical application of TROP2-targeted antibody-drug conjugates in non-small cell lung cancer (2026 edition)

Expert consensus on the clinical application of TROP2-targeted antibody-drug conjugates in non-small cell lung cancer (2026 edition)

Journal: Zhonghua zhong liu za zhi [Chinese journal of oncology]

Published: March 24, 2026

Authors' reply to "Outcomes for metastatic triple-negative breast cancer patients treated with sacituzumab govitecan in clinical studies and real-world studies: a single-arm meta-analysis".

Authors' reply to "Outcomes for metastatic triple-negative breast cancer patients treated with sacituzumab govitecan in clinical studies and real-world studies: a single-arm meta-analysis".

Journal: European journal of clinical pharmacology

Published: March 17, 2026

Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers.

Targeted biologics for TNBC: Advances in nanobodies, antibodies, peptides, and aptamers.

Journal: Molecular therapy. Oncology

Published: February 20, 2026

TROP2-targeted ADCs demonstrate survival benefit for patients with advanced triple-negative breast cancer: Almost a 3-month improvement was seen in median PFS for patients assigned to sacituzumab govitecan in comparison to those assigned to chemotherapy.

TROP2-targeted ADCs demonstrate survival benefit for patients with advanced triple-negative breast cancer: Almost a 3-month improvement was seen in median PFS for patients assigned to sacituzumab govitecan in comparison to those assigned to chemotherapy.

Journal: Cancer

Published: February 19, 2026

Sacituzumab govitecan in breast cancer patients - an evaluation of progression-free survival, overall survival, and hypersensitivity reactions in real-world patients.

Sacituzumab govitecan in breast cancer patients - an evaluation of progression-free survival, overall survival, and hypersensitivity reactions in real-world patients.

Journal: Journal of oncology pharmacy practice : official publication of the International Society of Oncology Pharmacy Practitioners

Published: February 16, 2026

Sacituzumab govitecan plus pembrolizumab improves outcomes.

Sacituzumab govitecan plus pembrolizumab improves outcomes.

Journal: Nature reviews. Clinical oncology

Published: February 11, 2026

An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triplenegative breast cancer: Erratum.

An integrated analysis of Sacituzumab govitecan in relapsed or refractory metastatic triplenegative breast cancer: Erratum.

Journal: Medicine

Published: February 06, 2026

Showing 1-12 of 667

Last Updated: 04/28/2026